Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol

JULIAN KENYON; WAI LIU; ANGUS DALGLEISH

doi:10.21873/anticanres.12924

Article Figures & Data

Figures

Tables

Download figure
Open in new tab
Download powerpoint
Figure 1.
Patient with ependymoma. A) A scan on the 6th of Jan 2016 showed enlargement of the posterior fossa mass. There were some, particularly multimodal features of radionecrosis, but in the context of a previously rapidly progressive tumour, an element of disease progression was also being considered. B) A subsequent scan on the 13th April 2016 showed further tumour progression and development of moderately severe supratentorial hydrocephalus. C) On the 30 Sept 2016, scans showed substantial improvement/reduction in size of the residual disease. There had been a substantial improvement in appearances, with marked reduction in size of the posterior fossa tumour from 3.4×3.2 cm in the sagittal plane to 1.7×1.7 cm. D) Scans performed on the 14th Dec 2016, showed a slow improvement; with impressive resolution of left CPA recurrent ependymoma.
Download figure
Open in new tab
Download powerpoint
Figure 2.
Patient with tanycytic ependymoma. A) A scan on the 13th Jan 2017 showed a reduction in the size and enhancement of the left periventricular tumour. There was almost complete resolution of the parenchymal enhancement with a couple of small ependymal nodules remaining, but slightly smaller. There was no significant change in the T2/FLAIR appearance with Wallarian degeneration extending into the corticospinal tracts. B) A follow-up scan performed on the 21 Feb 2018 revealed evidence of disease progression with a near doubling of the enhancing soft tissue arising from the ependymal surface of the left lateral ventricle and projecting into the body of the left lateral ventricle. There are new enhancing foci in the left putamen and subthalamic region with further non-enhancing T2 hyperintense tumour expanding inferiorly into the left cerebral peduncle.